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Abstract 
Background. Peritoneal catheter tunnel and exit-site infection (TESI) complicates the clinical course of 
peritoneal dialysis (PD) patients. Adherence to recommendations for catheter insertion, exit-site care, and 
management of Staphylococcus aureus (SAu) carriage reduces, but does not abrogate the risk of these 
infections. 
Objective. To reappraise the risk profile for TESI in an experienced center with a long-term focus on 
management of SAu carriage and a low incidence of these infections. 
Method. Following a retrospective, observational design, we investigated 665 patients incident on PD. The 
main study variable was survival to the first episode of TESI. We considered selected demographic, clinical, 
and technical variables, applying multivariate strategies of analysis. 
Main results. The overall incidence of TESI was 1 episode/68.5 patient-months. Staphylococcus 
aureus carriage disclosed at inception of PD (but not if observed sporadically during follow-up) (hazard ratio 
[HR] 1.53, p = 0.009), PD started shortly after catheter insertion (HR 0.98 per day, p = 0.011), PD after 
kidney transplant failure (HR 2.18, p = 0.017), lower hemoglobin levels (HR 0.88 per g/dL, p = 0.013) and 
fast peritoneal transport rates (HR 2.92, p = 0.03) portended an increased risk of TESI. Delaying PD ≥ 30 
days after catheter insertion markedly improved the probability of TESI. Carriage of methicillin-resistant SAu 
since the start of PD was associated with a high incidence of TESI by these bacteria. On the contrary, 
resistance to mupirocin did not predict such a risk, probably due to the use of an alternative regime in affected 
patients. 
Conclusions. Adherence to current recommendations results in a low incidence of TESI in PD patients. 
Interventions on specific risk subsets have a potential to bring incidence close to negligible levels. Despite 
systematic screening and management, SAu carriage is still a predictor of TESI. Antibiotic susceptibility 
patterns may help to refine stratification of the risk of TESI by these bacteria. Early insertion of the peritoneal 
catheter should be considered whenever possible, to reduce the risk of later TESI. 
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Infections affecting the tunnel and the exit-site of permanent peritoneal catheters (TESI) represent 
a significant source of morbidity and technique failure in peritoneal dialysis (PD) patients. These 
infections are able to progress to the peritoneal cavity and cause peritonitis (1), and may result 
directly in catheter removal and PD drop-out in a significant proportion of cases, despite 
significant advances in prevention and management during the last 2 decades (2). 
 
Most previous studies addressing factors which may influence the appearance of TESI have 
focused on Staphylococcus aureus (SAu) carriage, catheter design and insertion techniques, and 
exit-site care procedures (2,3). Screening and treatment of SAu carriers is the single measure with 
a best defined impact on the incidence of TESI (4,5), although few PD experts would not concur 
with the statements that thorough catheter insertion, adequate surgical scarring, and dedicated exit-
site care will help to prevent this complication (2,3,6-8). On the other hand, the information on 
other demographic or clinical factors with a potential impact on the incidence of TESI is limited, 
and often merged in the general topics of complications and survival of the peritoneal catheter. 
Establishing risk profiles for TESI in experienced settings could help at the time of planning 
further prevention strategies. 
 
We have undertaken an observational analysis of a large cohort of patients treated with PD in an 
experienced center with a low incidence of TESI. Our main objective was to disclose risk subsets 
which could be a subject of specific interventions to reduce the incidence of this complication. 
Population and Methods 
General Design 
Following a retrospective, observational design, we investigated the association of selected 
demographic, clinical and PD practice-related factors in patients incident on PD with the risk of 
developing TESI. The study setting was a tertiary hospital, University Hospital of A Coruña 
(UHAC), attending a median of 90 prevalent PD patients. The recruitment period was 1991 to 
2011, and follow-up was closed by June 2013. This time lapse was selected due to a remarkable 
homogeneity of protocols for prevention of PD-related infections, with only minor changes 
introduced during the study period (see below). The main study variable was survival to the first 
episode of TESI. Control variables were recovered from a prospective database including all 
patients starting PD in our unit during the same period. 
 
This study complied with the ethic requirements of our center for retrospective, observational 
studies. 
Study Population 
During the study period, 712 started PD in our unit. We considered 3 inclusion criteria: 
 
1. Minimum follow-up of 3 months after catheter insertion 
2. Minimum follow-up of 1 month on PD 
3. Baseline and follow-up clinical records available 
 
Six hundred and sixty-five patients fulfilled these inclusion criteria. The main characteristics of the 




Main Clinical Procedures and Definitions 
Systematic screening of SAu carriers and, when appropriate, PD partners (in cases of family-
assisted PD) was performed during the full study period. Samples were taken in triplicate from 
both nares and the pericatheter area. An individual was defined as a carrier whenever any of these 
samples was positive for SAu. Carriers were treated with nasal (3 times daily) and (since 1994) 
daily pericatheter mupirocin for 7 days, and then screened every other month for recolonization. 
Should the latter occur, mupirocin was applied again. We screened routinely in vitro susceptibility 
of SAu to methicillin and mupirocin. Colonization by mupirocin-resistant strains was managed 
thereafter with 2% fusidic acid ointment. Non-carriers were scrutinized for SAu yearly, and 
entered to the carriers protocol whenever a positivity for SAu was detected during follow-up. 
 
The following procedures have remained essentially unchanged during the study period. We used 
swan neck, double-cuff peritoneal catheters. Insertion was routinely carried out by a nephrologist. 
Surgical insertion was restricted to patients with suspected peritoneal adherences or needing a 
simultaneous surgical procedure. We administered cefazolin as antibiotic prophylaxis for catheter 
insertion. A delay of at least 2 weeks between insertion and initiation of PD was intended, but 
earlier initiation of PD was often preferred to central venous catheter-based hemodialysis. We 
protected the surgical wound and catheter exit site with closed dressings during 2 weeks after 
catheter insertion; this dressing was changed every 4 days before 2002, and weekly thereafter. 
Routine exit-site care was usually based on povidone iodine, with 2% saline or simple cleansing 
with soap and water reserved for specific indications (e.g. skin irritation). 
  
We used integrated Y systems for continuous ambulatory PD, and Home Choice (Baxter, 
Deerfield, IL, USA) cyclers for automated PD. We used classic PD solutions in the majority of 
cases; low-glucose degradation product solutions were introduced after March 2008. 
 
The diagnosis of peritonitis followed accepted standards (8). Tunnel and exit-site infection was 
diagnosed in the presence of at least 1 of: purulent discharge from the exit site, a combination of 
persistent serous or serohemorrhagic discharge plus a microbial isolation from the exit site, or the 
presence of overt signs of inflammation either around the exit site or in the subcutaneous catheter 
tunnel path. Mild, non-exudative inflammatory signs around the exit site were not recorded as 
infections. We do not routinely use tunnel sonography for routine screening or diagnostic work-up 
of TESI. Systemic antibiotics were used, according to in vitro susceptibility, for treatment of most 
TESI. Topical management was based on hypertonic saline, 0.3% ciprofloxacin solution, 0.3% 
gentamycin solution or 2% mupirocin ointment, as needed. Traumatized or equivocal exit sites 
were treated with topical 0.3% ciprofloxacin 2 times daily for a minimum of 5 days. 
Study Variables and Laboratory Methods 
The study variables were survival to the first episode (main) and incidence of TESI. We selected 
the catheter insertion date, rather than the PD initiation date, as the starting point for survival 
analyses. 
 
The baseline control variables scrutinized were: age, gender, kidney disease, diabetes, PD vintage, 
origin (conservative, failed transplant, hemodialysis), PD modality and solution (third month), 
SAu carriage, comorbidity (Charlson's score), malnutrition (subjective global assessment), 
socioeconomic background, ability for self-dialysis, body mass index, hemoglobin, albumin 
(autoanalyzer), glomerular filtration rate (mean of urea and creatinine clearances), peritoneal 
transport (D/P ratio of creatinine at 240’ D/Pcrea) and C-reactive protein (Immunoturbidimetry, 
Roche Diag., Mannheim, Germany). We also scrutinized the peritoneal catheter insertion 
technique and the delay between catheter insertion and initiation of PD. 
Strategy of Analysis and Statistics 
The main objective was to establish a predictive profile for TESI between catheter insertion and 
end of follow-up or termination of PD. We first compared patients who did or did not suffer TESI 
during follow-up. We then compared survival to the first episode of TESI according to the 
different independent variables. As a third step, we performed multivariate, adjusted estimations of 
the risk of suffering TESI during follow-up. 
 
Numeric variables are presented as mean ± standard deviation (SD), unless abnormally distributed 
(median with range). We used the Student t-test, ANOVA and Mann-Whitney test to compare 
numeric variables, and χ2 distribution and Fisher's test for categorized variables. Univariate 
analysis of survival to first TESI was carried out using Kaplan-Meier plots (log rank). Multivariate 
survival to the first episode of infection was produced by stepwise Cox regression analysis. 
Patients were censored in case of death, kidney transplant, transfer to hemodialysis or loss to 
follow-up. The same strategy was applied to identify predictors of TESI by SAu and gram-
negative bacteria. D/Pcrea (n = 377) and C-reactive protein (n = 490) were not available in a 
significant proportion of cases, and were analyzed in separate models. 
 




Analysis included 665 patients (Table 1). Two hundred and eighty-two patients (43.7%) carried 
SAu at the start of PD, of whom 46 (16.3%) did not show further positivity after a first course of 
mupirocin. On the other hand, 81 of 245 patients negative for SAu at the start of PD were positive 
for this bacteria at some point during follow-up, yielding a final accumulated incidence of SAu 
positivity of 56.2%. Only 18 patients (2.7% of all patients, 6.4% of carriers) had methicillin-
resistant SAu (MRSAu) isolated at the start of PD, but 95 (14.3% of all patients) did so at least 
once during follow-up. Regarding mupirocin, resistance was a rare event among SAu until the late 
1990s, increasing rather abruptly and then stabilizing in the ensuing years, for an accumulated 
incidence of 24.0% between 2000 and 2012. Unfortunately, our screening protocol did not 
differentiate low-degree (minimum inhibitory concentration ≥ 8 μg/mL) from high degree 
(minimum inhibitory concentration ≥ 512 μg/mL) resistance, although the former may have been 
more frequent than the latter. Resistance of SAu to mupirocin since the start of PD was a rare 
event (n = 7). 
 
We recorded 230 episodes of TESI in 176 patients (1 episode in 129 patients, 2 in 36 patients and 
more than 2 episodes in 11 patients), for an overall incidence of 1 episode/68.5 patient-
months. Table 2 displays the etiologic spectrum of TESI. Peritoneal catheter removal was 
necessary in 55 episodes (23.9 %) of TESI, including 9 cases (3.9%) of permanent discontinuation 
of PD. Simultaneous or secondary peritoneal infection was the most usual indication for catheter 




Table 3 displays univariate comparisons according to the presence of TESI during follow-up. 
Univariate survival analysis (Kaplan-Meier) provided similar results, indicating that PD vintage 
(p < 0.0005), SAu carriage (p = 0.001), PD after transplant failure (p = 0.02), delay between 
catheter insertion and PD inception ≥ 30 days (p < 0.001) (Figure 1), and hemoglobin < 10 g/dL 
(p = 0.02) were associated with an increased risk of TESI, with non-significant trends for low 






Figure 1 Survival to first episode of TESI according to delay between peritoneal catheter insertion and 
initiation of PD. TESI = tunnel and exit-site infection. 
Multivariate Analysis 
Cox's models confirmed PD vintage (Figure 2), SAu carriage, shorter delay between catheter 
insertion and initiation of dialysis, PD after kidney transplant failure, and lower baseline 
hemoglobin as independent predictors of TESI (Table 4). Importantly, categorization of delay 
between catheter insertion and initiation of PD showed that the improvement in the probability of 
TESI was not linear. A lapse ≥ 30 days (n = 225) was associated with a lower risk than < 7 days 
(n = 94) (HR 1.40, 95% CI 0.91 – 2.35, p = 0.13), 7 – 14 days (n = 110) (HR 1.69, 95% CI 1.03 – 
2.79, p = 0.040), and, remarkably, 15 – 30 days (n = 222) (HR 1.94, 95% CI 1.29 – 2.95, p = 





Figure 2 Hazard ratios of TESI by year of start of dialysis (modeled by splines with 7 degrees of freedom) 
and time of follow-up. Adjusted for main covariates (p < 0.001 Cox). TESI = tunnel and exit-site infection; 
CI = confidence interval. 
 
 
Secondary models showed an increased risk of TESI for fast transporters (HR 2.92 vs low 
transporters, 95% CI 1.10 – 7.73, p = 0.03) (-2 log likelihood 817.3, global model χ2 32.87, p < 
0.001). 
Subanalyses for Different Agents of Tesi 
Tunnel and exit-site infection by SAu appeared earlier than those caused by gram-negative 
bacteria (15.8 ± 1.7 vs 21.2 ± 3.0 months, p = 0.031). Univariate analysis disclosed a roughly 
coincident risk profile between TESI by SAu and the general profile (Table 2). In terms of TESI 
by gram-negative bacteria, only fast peritoneal transport rates (p = 0.026) and higher C-reactive 
protein (median 0.95 vs 0.56 mg/dL, p = 0.037) sustained a significant association. 
  
Staphylococcus aureus carriage was a predictor of TESI by SAu only when present since the start 
of PD, but not for patients negative at inception and positive during follow-up (Figure 3). The 
same applied for MRSAu (Figure 4). Appearance of resistance to mupirocin during follow-up did 
not portend an increased risk of TESI by SAu (p = 0.85, log rank). The impact of baseline 




Figure 3 Survival to first episode of TESI by SAu according to carriage of SAu, either detected since 
inception of PD or later during follow-up. TESI = tunnel and exit-site infection; SAu = Staphylococcus 




Figure 4 Survival to first episode of TESI by SAu according to carriage of MRSAu, either detected since 
inception of PD or later during follow-up. TESI = tunnel and exit-site infection; SAu = Staphylococcus 
aureus; MRSAu = methicillin-resistant SAu; PD = peritoneal dialysis. 
 
  
Multivariate analysis identified SAu carriage (HR 1.97, 95% CI 1.25 – 2.95, p = 0.006), delay 
between catheter insertion and initiation of PD (HR < 7 days vs ≥ 30 days 1.77, 95% CI 1.12 – 
3.03, p = 0.04), plasma albumin (HR 0.96 per g/dL, 95% CI 0.92 – 0.99, p = 0.044), and PD after 
transplant failure (HR 3.05, 95% CI 1.36 – 5.84, p = 0.007) as independent predictors of TESI by 
SAu. On the other hand, fast peritoneal transport (HR 1.05, 95% CI 1.02 – 1.08, p = 0.003) was 
the only consistent predictor of TESI by gram-negatives, with similar trends for lower glomerular 
filtration rate (p = 0.07) and hemoglobin levels (p = 0.06) but, in general, the study was 
underpowered to model adequately the latter complication. 
 
Multivariate subanalyses for TESI by SAu confirmed that SAu carriage at inception (HR 2.49, 
95% CI 1.28 – 4.78, p = 0.007) but not if observed later (HR 1.53, 95% CI 0.66 – 3.56, p = 0.32) 
portended a high risk of this complication. On the other hand, a similar, non-significant trend 
applied for carriage of MRSAu, with HR 2.19 (95% CI 0.96 – 4.83, p = 0.07) for carriers at the 
start of PD, as compared with HR 0.82 (0.41 – 1.86, p = 0.59) for late positivity (comparison with 
SAu carriers who were never positive for MRSAu). Resistance to mupirocin during follow-up did 
not carry a significant risk of TESI by SAu (p = 0.87). 
Discussion 
TESI represents a significant source of morbidity, technique failure and even mortality among PD 
patients (9). The incidence of these infections shows a remarkable variability among different 
centers (10-13). Adherence to recommendations for prevention and management (2,3,8) permits 
keeping the incidence of TESI in the vicinity of 1 episode every 5 patient-years, or even lower, as 
occurred in our unit. Even in this scenario, further reduction in the incidence of this complication 
is desirable. Exploration of demographic and clinical factors associated with a risk of TESI may 
help to refine prevention, once all the essential recommendations have been fulfilled. 
 
There is a relative paucity of studies comprehensively exploring the risk profile for TESI. 
Moreover, a majority (10,14-16) were carried out during earlier years of PD and may not be 
representative of the current status of the problem. Staphylococcus aureus carriage has been a 
long-term subject of attention. Several randomized studies and metaanalyses indicate that 
mupirocin (4,5) and other antibiotic protocols (11,17) can markedly reduce the incidence of TESI, 
mainly by SAu, but also by other bacteria. On the other hand, studies addressing the role of 
technical factors have yielded less consistent results. An overview of these analyses suggests that 
neither the catheter type nor the insertion technique bear a clear influence on the later incidence of 
TESI (3), although double-cuff designs and downward orientation of the exit site offer some 
potential, not unequivocal advantages (2). Antibiotic prophylaxis for catheter insertion is more 
clearly endorsed by evidence (3). On the other hand, a minimal delay between catheter insertion 
and PD inception is advisable, to permit correct epithelization of the subcutaneous exit-site track 
(6). Two weeks is the International Society for Peritoneal Dialysis recommendation for this 
purpose (3). Finally, correct care of the exit site can also reduce the risk of TESI (14), although the 
optimal procedures (frequency of cure, types of disinfectant and dressing, etc.) have not been 
established (7). 
 
Available information about how demographic and other clinical factors may influence the 
appearance of TESI is clearly insufficient. Older studies indicated that obesity (6), younger age 
(10,18) and a longer stay on PD (19) could favor the development of this complication. A recent 
report has suggested that new, biocompatible solutions may be associated with a lower incidence 
of TESI (20), although a before-after design limits the reliability of this finding. Tunnel and exit-
site infection appears to be similarly frequent in patients treated with continuous ambulatory PD 
and automated PD (19,21). 
  
Our study provides some potentially consequential clues to the question. Importantly, our data 
suggest that a delay of at least 1 month between catheter insertion and initiation of PD may be 
more appropriate to prevent TESI than the current International Society for Peritoneal Dialysis 
recommendation of 2 weeks (Figure 1) (3). These findings emphasize the convenience of 
permitting complete scarring of the catheter tunnel and exit site, and challenge the extended 
practice of holding off on catheter insertion until the need for dialysis is impending.  
 
The decline in the incidence of TESI during the second half of the study period (Figure 2) suggests 
a global improvement in the quality of care protocols, which may not be captured by specific 
variables. On the other hand, and despite our long-term experience in screening and management 
(22), SAu carriage was still an independent predictor of TESI by the same bacteria. Several factors 
may have contributed to the persistence of this association. For instance, SAu carriage may signal 
patients with a predisposition to infection by this bacteria, which local nasal and pericatheter-
oriented management may not reverse completely. In addition, the optimal approach for screening 
and treating carriers is yet to be established (23). On the other hand, in a previous study, we 
reported that resistance of SAu to mupirocin may favor TESI (24) but the use of an alternative 
regime (2% fusidic acid) appeared to abrogate this risk, in more recent years. Other regimes 
(11,18) may be similarly effective for this purpose, although the use of polysporin triple ointment 
may associate a deterrent increase in the incidence of fungal infections (18). Overall, our results 
support monitoring the susceptibility of SAu to agents used for eradication of this bacteria, as well 
as implementing alternative management strategies in case of resistance. 
 
Isolation of MRSAu at the start of PD portended a particularly high risk of TESI by SAu during 
follow-up. Interestingly, the risk of TESI by SAu (or MRSAu) was restricted to patients incident 
on PD, but not for those positive during follow-up (Figures 3 and 4). The significance of this 
finding is not clear, but we suggest that our initial screening protocol (including sampling in 
triplicate) may be efficient to detect real, persistent carriers, as opposed to late isolations, which 
could reflect inconsistent or sporadic colonizations. 
 
Patients starting PD after kidney transplant failure were at particular risk of TESI. 
Immunosuppression and deficient scarring likely contributed to this association. We are unaware 
of previous studies assessing this question, but the risk of peritonitis has been reported to be either 
similar (25) or increased (26) in these patients. A particular attention to early catheter insertion and 
postoperative wound and exit-site care is seemingly warranted in this setting. 
 
Lower hemoglobin levels and fast peritoneal transport rates showed a consistent association with 
the probability of suffering TESI. The explanation for these findings is not clear. Anemia is a 
marker of comorbidity and poor general condition, which may set a generic predisposition to 
infection. We are unaware of previous reports relating fast creatinine peritoneal transport with the 
risk of infection in PD, but some studies have detected this association in patients with large pore 
dysfunction, a condition often linked to fast peritoneal transport (27,28). 
 
Diabetics did not show an increased incidence of TESI, in agreement with former studies (29). A 
recent investigation from our unit suggested that the risk of TESI in diabetics may be linked to 
metabolic control (30). Surgical insertion of the peritoneal catheter did not carry a different risk of 
TESI than insertion by a nephrologist. This finding could be somewhat unexpected, because 
patients with a surgically inserted catheter had a more complicated profile, including preexisting 
abdominal disease, and simultaneous surgery. 
  
Our study suffers significant limitations, including a retrospective, single-center design, which 
leaves open the possibility of bias by selection. Moreover, the homogeneity of clinical procedures 
prevented analysis of some potential risk factors for TESI, including catheter design and exit-site 
care procedures. On the other hand, this report provides clear insights into the risk profile for TESI 
in a low-incidence setting, pointing to some subsets of patients as targets for intensified 
prevention, and showing that early catheter insertion may be very effective to avoid this 
complication. The incidence of TESI in 104 patients initiating PD after 2000, who were not SAu 
carriers and who respected a delay of ≥ 30 days to start PD after catheter insertion was 1 
episode/257.8 patient-months, close to negligible, suggesting that eradication of TESI as a concern 
in PD units may be a realistic objective. 
 
In summary, TESI still complicates the clinical course of PD patients. Adherence to recommended 
clinical procedures markedly reduces the incidence of this infection. Categorization of high-risk 
subsets, including SAu carriers and patients starting PD after failure of a kidney transplant, may 
permit individualized interventions, to further reduce the impact of TESI. Particular attention 
should be paid to the susceptibility patterns of SAu to methicillin and antibiotics used for 
eradication of this bacteria (including mupirocin), and specific management strategies should be 
designed for resistant strains. Early insertion of the peritoneal catheter appears to be a very 
effective measure to reduce the later incidence of TESI. 
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